Korea Botox Rivalry To Intensify After Meditoxin Measures
Punitive Steps To Impact Market
Executive Summary
As South Korea’s drug ministry decides to rescind approval of Medytox’s botulinum toxin product following manipulation of manufacturing and quality control documents, competition among existing rivals and newcomers is expected to further intensify.
You may also be interested in...
Medytox Faces Botulinum Approval Cancellation Over Data Issues
Leading South Korean botulinum toxin company Medytox is facing substantial business risk as its Meditoxin product is suspended amid test result manipulation investigations.
Helixmith Plunges On Warning Of Possible Offering Delay
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.
SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
Need a specific report? 1000+ reports available
Buy Reports